Adjuvant Capital launches US$300m Global Health Technology Fund for medical innovations

AFRICA – Adjuvant Capital, a life sciences investment firm focused on global health, has announced an oversubscribed US$300 million Global Health Technology Fund, focused on accelerating the development of medical innovations for historically overlooked public health challenges. Launched in 2019, Adjuvant’s debut fund will support promising new technologies for indications that the venture capital industry has largely ignored. “Billions of people around the world live under constant assault from diseases like malaria, shigella, hookworm, tuberculosis, and Lassa fever, yet Wall Street and Silicon Valley typically pay little attention to these…

Read More